Compare Ginkgo Bioworks Holdings Inc (DNA) vs Sibanye Stillwater Ltd (SBSW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Sibanye Stillwater Ltd — how do they compare? Ginkgo Bioworks Holdings Inc trades at $8.93 (market cap $590.53M), while Sibanye Stillwater Ltd trades at $8.39 (market cap $6.03B). The key difference: Sibanye Stillwater Ltd is far larger — about 10.2× Ginkgo Bioworks Holdings Inc's market cap, and Sibanye Stillwater Ltd pays a 3.63% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals.
| DNA | SBSW | |
|---|---|---|
Market Cap | $590.53M | $6.03B |
Sector | Health | Basic Materials |
52-Week High | $16.14 | $21.12 |
52-Week Low | $5.48 | $7.27 |
Enterprise Value | $627.78M | $7.66B |
Dividend Yield | — | 3.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DNA trades at $9.05, down 0.44% on the day, reflecting ongoing investor caution. The technical outlook is bearish, while fundamentals show significant losses with a net income margin of -201.05% and negative cash flows. Recent earnings have been mixed, missing estimates in two of the last three quarters. Analyst sentiment is divided, with a slight lean toward buy ratings amid high volatility and operational challenges.
The outlook remains challenging due to persistent losses and cash burn, though analyst coverage suggests potential long-term value. Key risks include execution missteps and intense competition in biotechnology. Investment appeal hinges on future profitability improvements and successful business model execution.
Sibanye Stillwater (SBSW) trades at $8.42, down 1.52% with bearish technical signals. The company shows mixed fundamentals with a negative net income margin of -3.99% and ROE of -12.38% for 2024, though revenue has stabilized at $112.13B. Recent news highlights a turnaround narrative with EBITDA growth and debt reduction plans. Technical indicators show bearish momentum with support at $8 and resistance at $9.
The stock presents a high-risk opportunity with significant upside to the $14.25 consensus price target. Key risks include persistent negative profitability, high debt levels, and commodity price volatility. Analyst sentiment is cautiously optimistic with 43% buy ratings, but investors should weigh the turnaround potential against ongoing operational challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Sibanye Stillwater Ltd
Sibanye Stillwater Ltd is a South Africa-focused mining company. The Group currently owns and operates five underground and surface gold operations in South Africa: the Cooke, DRDGOLD, Driefontein, and Kloof operations in the West Witwatersrand region, and the Beatrix Operation in the southern Free State province. In addition to mining, the company owns and manages extraction and processing facilities at its operations, where gold-bearing ore is treated and beneficiated to produce gold dore. The gold dore is further refined at Rand Refinery into gold bars with a purity of at least 99.5% and is then sold on international markets. Sibanye holds a 44% interest in Rand Refinery, global refiners of gold, and the largest in Africa. Rand Refinery markets gold to customers around the world.
Read more on SBSW →
